Eli Lilly and Company has taken the lead terzipetide supplier in in the development and tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, showcases significant ability to improve glycemic contro… Read More